Skip to main content

Table 6 Percent of cells on day 21 following the therapy, normalized to the initial levels before the therapy. Values above 100 indicate the cell counts have increased above the initial levels

From: Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen

Patient number Breast cancer stage CD8 + perforin + T cells CD123+ CD11+ CD25 + CD127–
After the 1st round of chemotherapy After the 3rd round of chemotherapy After the 1st round of chemotherapy After the 3rd round of chemotherapy After the 1st round of chemotherapy After the 3rd round of chemotherapy After the 1st round of chemotherapy After the 3rd round of chemotherapy
FAC chemotherapy + Placebo
 02–12a IIIA 122.2 111.1 440.9 118.2 150.5 30.9 26.8 34.1
 02–07 IIIB 46.7 105.6 80.0 176.7 43.8 200.0 220.8 54.7
FAC chemotherapy + Panagen
 02–02 IIA 300.0 420.0 92.3 615.4 92.9 333.3 1.1 81.8
 02–10 IIA 178.6 178.6 543.8 37.5 666.7 83.3 120.0 62.0
 02–03 IIA 100.0 23.3 61.4 59.1 41.1 41.1 4.5 116.7
 02–11a IIB 123.5 58.8 310.3 34.5 66.1 14.0 16.7 133.3
 02–15 IIIA 33.3   26.9 23.1 54.8 19.4 69.2 69.2
 02–05 IIIB 39.4 106.3 35.3 220.6 62.7 178.0 180.0 160.0
 02–14 IIIB -   153.8 123.1 97.7 85.2 127.3 118.2
 02–01 IIIB 200.0 525.0 263.0 42.0 150.0 42.0 200.0 200.0
 02–08 IIIB 61.8 117.6 88.2 188.2 204.8 202.4 175.0 300.0
  1. Note: a – tamoxifen treatment. Patients who progressed or died are shown in boldface